Inozyme Historical Balance Sheet

INZY Stock

USD 0.96 0.05 4.75%

Trend analysis of Inozyme Pharma balance sheet accounts such as Total Current Liabilities of 35.6 M or Total Stockholder Equity of 84.4 M provides information on Inozyme Pharma's total assets, liabilities, and equity, which is the actual value of Inozyme Pharma to its prevalent stockholders. By breaking down trends over time using Inozyme Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Inozyme Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inozyme Pharma is a good buy for the upcoming year.

Inozyme Pharma Inventory

(138,862)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

About Inozyme Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Inozyme Pharma at a specified time, usually calculated after every quarter, six months, or one year. Inozyme Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inozyme Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inozyme currently owns. An asset can also be divided into two categories, current and non-current.

Inozyme Pharma Balance Sheet Chart

At this time, Inozyme Pharma's Capital Surpluse is fairly stable compared to the past year. Total Current Assets is likely to rise to about 126.6 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 9 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Inozyme Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inozyme Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Inozyme Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inozyme Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Inozyme Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.At this time, Inozyme Pharma's Capital Surpluse is fairly stable compared to the past year. Total Current Assets is likely to rise to about 126.6 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 9 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	10.5M	12.6M	16.0M	9.0M
Total Assets	139.2M	200.8M	123.2M	133.2M

Other Current Liab Total Assets

Inozyme Pharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital
Total Assets		0.86	0.67	0.97	0.94	0.84	-0.04	-0.78	0.75	0.36	0.74	0.86	0.77	1.0	0.73	0.77	1.0	-0.74	0.91	0.89	0.83	-0.56	0.81	0.99	1.0	0.99
Other Current Liab	0.86		0.86	0.79	0.89	0.72	0.25	-0.94	0.73	0.02	0.47	0.7	0.54	0.85	0.85	0.97	0.89	-0.63	0.95	0.98	0.97	-0.33	0.87	0.87	0.88	0.81
Total Current Liabilities	0.67	0.86		0.59	0.71	0.54	0.3	-0.96	0.67	-0.04	0.26	0.54	0.46	0.65	0.92	0.84	0.69	-0.54	0.9	0.82	0.79	-0.27	0.7	0.67	0.68	0.59
Total Stockholder Equity	0.97	0.79	0.59		0.95	0.91	-0.17	-0.69	0.83	0.44	0.84	0.94	0.82	0.97	0.58	0.66	0.96	-0.86	0.87	0.8	0.77	-0.74	0.76	0.98	0.96	0.96
Net Tangible Assets	0.94	0.89	0.71	0.95		0.86	-0.14	-0.77	0.9	0.39	0.8	0.9	0.81	0.93	0.66	0.78	0.95	-0.87	0.92	0.88	0.85	-0.66	0.84	0.97	0.93	0.89
Property Plant And Equipment Net	0.84	0.72	0.54	0.91	0.86		0.0	-0.63	0.8	0.19	0.74	0.97	0.63	0.82	0.43	0.54	0.84	-0.89	0.82	0.68	0.74	-0.8	0.74	0.87	0.82	0.82
Net Debt	-0.04	0.25	0.3	-0.17	-0.14	0.0		-0.39	-0.33	-0.93	-0.65	-0.2	-0.63	-0.05	0.32	0.37	0.0	0.29	0.16	0.25	0.39	0.43	0.04	-0.05	0.02	-0.03
Retained Earnings	-0.78	-0.94	-0.96	-0.69	-0.77	-0.63	-0.39		-0.64	0.09	-0.29	-0.6	-0.44	-0.77	-0.94	-0.93	-0.8	0.54	-0.95	-0.92	-0.91	0.25	-0.77	-0.78	-0.8	-0.73
Accounts Payable	0.75	0.73	0.67	0.83	0.9	0.8	-0.33	-0.64		0.47	0.83	0.89	0.84	0.73	0.5	0.57	0.75	-0.93	0.82	0.66	0.64	-0.78	0.76	0.79	0.72	0.67
Cash	0.36	0.02	-0.04	0.44	0.39	0.19	-0.93	0.09	0.47		0.78	0.4	0.83	0.38	0.01	-0.09	0.32	-0.42	0.13	0.06	-0.12	-0.51	0.17	0.36	0.31	0.36
Non Current Assets Total	0.74	0.47	0.26	0.84	0.8	0.74	-0.65	-0.29	0.83	0.78		0.85	0.93	0.74	0.22	0.28	0.72	-0.83	0.57	0.46	0.38	-0.81	0.61	0.76	0.7	0.72
Non Currrent Assets Other	0.86	0.7	0.54	0.94	0.9	0.97	-0.2	-0.6	0.89	0.4	0.85		0.77	0.85	0.42	0.52	0.85	-0.94	0.82	0.65	0.68	-0.86	0.74	0.89	0.84	0.84
Other Assets	0.77	0.54	0.46	0.82	0.81	0.63	-0.63	-0.44	0.84	0.83	0.93	0.77		0.77	0.45	0.4	0.75	-0.77	0.65	0.55	0.41	-0.7	0.63	0.77	0.73	0.73
Cash And Short Term Investments	1.0	0.85	0.65	0.97	0.93	0.82	-0.05	-0.77	0.73	0.38	0.74	0.85	0.77		0.72	0.76	1.0	-0.73	0.9	0.88	0.82	-0.56	0.8	0.99	1.0	0.99
Net Receivables	0.73	0.85	0.92	0.58	0.66	0.43	0.32	-0.94	0.5	0.01	0.22	0.42	0.45	0.72		0.88	0.74	-0.34	0.84	0.87	0.78	-0.06	0.69	0.7	0.75	0.69
Common Stock Shares Outstanding	0.77	0.97	0.84	0.66	0.78	0.54	0.37	-0.93	0.57	-0.09	0.28	0.52	0.4	0.76	0.88		0.8	-0.45	0.87	0.96	0.95	-0.12	0.77	0.77	0.8	0.72
Short Term Investments	1.0	0.89	0.69	0.96	0.95	0.84	0.0	-0.8	0.75	0.32	0.72	0.85	0.75	1.0	0.74	0.8		-0.74	0.92	0.91	0.86	-0.54	0.84	0.99	1.0	0.98
Non Current Liabilities Total	-0.74	-0.63	-0.54	-0.86	-0.87	-0.89	0.29	0.54	-0.93	-0.42	-0.83	-0.94	-0.77	-0.73	-0.34	-0.45	-0.74		-0.76	-0.58	-0.62	0.93	-0.6	-0.8	-0.71	-0.69
Capital Surpluse	0.91	0.95	0.9	0.87	0.92	0.82	0.16	-0.95	0.82	0.13	0.57	0.82	0.65	0.9	0.84	0.87	0.92	-0.76		0.92	0.92	-0.53	0.84	0.92	0.91	0.86
Other Current Assets	0.89	0.98	0.82	0.8	0.88	0.68	0.25	-0.92	0.66	0.06	0.46	0.65	0.55	0.88	0.87	0.96	0.91	-0.58	0.92		0.95	-0.28	0.84	0.89	0.9	0.85
Other Stockholder Equity	0.83	0.97	0.79	0.77	0.85	0.74	0.39	-0.91	0.64	-0.12	0.38	0.68	0.41	0.82	0.78	0.95	0.86	-0.62	0.92	0.95		-0.34	0.76	0.85	0.85	0.79
Total Liab	-0.56	-0.33	-0.27	-0.74	-0.66	-0.8	0.43	0.25	-0.78	-0.51	-0.81	-0.86	-0.7	-0.56	-0.06	-0.12	-0.54	0.93	-0.53	-0.28	-0.34		-0.35	-0.62	-0.52	-0.55
Deferred Long Term Liab	0.81	0.87	0.7	0.76	0.84	0.74	0.04	-0.77	0.76	0.17	0.61	0.74	0.63	0.8	0.69	0.77	0.84	-0.6	0.84	0.84	0.76	-0.35		0.79	0.81	0.75
Net Invested Capital	0.99	0.87	0.67	0.98	0.97	0.87	-0.05	-0.78	0.79	0.36	0.76	0.89	0.77	0.99	0.7	0.77	0.99	-0.8	0.92	0.89	0.85	-0.62	0.79		0.99	0.98
Total Current Assets	1.0	0.88	0.68	0.96	0.93	0.82	0.02	-0.8	0.72	0.31	0.7	0.84	0.73	1.0	0.75	0.8	1.0	-0.71	0.91	0.9	0.85	-0.52	0.81	0.99		0.99
Net Working Capital	0.99	0.81	0.59	0.96	0.89	0.82	-0.03	-0.73	0.67	0.36	0.72	0.84	0.73	0.99	0.69	0.72	0.98	-0.69	0.86	0.85	0.79	-0.55	0.75	0.98	0.99

Click cells to compare fundamentals

Inozyme Pharma Account Relationship Matchups

Inozyme Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	169.4M	123.5M	139.2M	200.8M	123.2M	133.2M
Other Current Liab	6.9M	7.8M	10.5M	12.6M	16.0M	9.0M
Total Current Liabilities	10.0M	11.6M	14.7M	14.7M	33.9M	35.6M
Total Stockholder Equity	158.1M	109.3M	118.6M	140.5M	57.8M	84.4M
Net Tangible Assets	(33.2M)	158.1M	109.3M	118.4M	136.2M	74.5M
Property Plant And Equipment Net	2.6M	4.4M	3.6M	2.6M	1.3M	2.4M
Net Debt	(158.6M)	(19.9M)	(26.1M)	12.0M	(5.7M)	(5.9M)
Retained Earnings	(91.1M)	(147.7M)	(214.8M)	(285.9M)	(388.0M)	(368.6M)
Accounts Payable	3.1M	2.4M	2.5M	1.2M	2.5M	2.1M
Cash	159.9M	23.3M	32.9M	34.6M	21.1M	38.8M
Non Current Assets Total	18.4M	8.2M	7.8M	4.6M	2.5M	2.4M
Non Currrent Assets Other	3.5M	3.4M	3.8M	2.0M	1.2M	2.2M
Cash And Short Term Investments	159.9M	111.8M	127.9M	188.6M	113.1M	124.4M
Net Receivables	155K	62K	115K	385K	442.8K	464.9K
Common Stock Shares Outstanding	23.4M	23.6M	37.8M	51.8M	62.8M	36.1M
Short Term Investments	119.7M	88.5M	95.0M	154.0M	92.0M	89.9M
Liabilities And Stockholders Equity	169.4M	123.5M	139.4M	200.8M	123.2M	133.2M
Non Current Liabilities Total	1.3M	2.6M	6.1M	45.7M	31.5M	25.2M
Capital Surpluse	1.4M	249.2M	256.9M	333.4M	383.4M	402.5M
Other Current Assets	3.3M	3.5M	3.4M	7.3M	7.6M	4.0M
Other Stockholder Equity	79.8M	256.9M	333.4M	426.4M	445.7M	230.5M
Total Liab	11.3M	14.3M	20.8M	60.4M	65.4M	35.5M
Net Invested Capital	158.1M	109.3M	122.5M	185.2M	103.8M	99.3M
Total Current Assets	151.0M	115.3M	131.4M	196.3M	120.7M	126.6M
Accumulated Other Comprehensive Income	2K	18K	(205K)	41K	69K	72.5K
Net Working Capital	141.0M	103.7M	116.7M	181.6M	86.8M	112.3M
Property Plant Equipment	298K	2.6M	4.4M	2.0M	2.3M	2.1M
Property Plant And Equipment Gross	2.6M	5.4M	5.4M	5.0M	4.5M	4.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inozyme Historical Balance Sheet

Inozyme Pharma Inventory

(138,862)

About Inozyme Balance Sheet Analysis

Inozyme Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Inozyme Pharma balance sheet Correlations

Inozyme Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inozyme Pharma balance sheet Accounts

Also Currently Popular

Additional Tools for Inozyme Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Short Term Investments

Retained Earnings	- 0.96	Total Current Liabilities
Capital Surpluse	- 0.95	Retained Earnings
Non Current Liabilities Total	- 0.94	Non Currrent Assets Other
Net Receivables	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Other Current Liab
Non Current Liabilities Total	- 0.93	Accounts Payable